Please ensure Javascript is enabled for purposes of website accessibility

Neptune Technologies (NEPT) Q3 2021 Earnings Call Transcript

By Motley Fool Transcribing - Feb 16, 2021 at 11:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NEPT earnings call for the period ending December 31, 2020.

Logo of jester cap with thought bubble.

Image source: The Motley Fool.

Neptune Technologies (NEPT -1.31%)
Q3 2021 Earnings Call
Feb 16, 2021, 8:30 a.m. ET

Contents:

  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:


Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Neptune Wellness Solutions Inc. third-quarter earnings conference call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session.

[Operator instructions] Please be advised that today's conference is being recorded. [Operator instructions] I would now like to hand the conference over to your host, Ms. Megan McGrath. Thank you.

Please go ahead.

Unknown speaker

Good morning, everyone, and thank you for joining us. Yesterday afternoon, we issued a press release, announcing our results for the third quarter of fiscal 2021. We also issued our management discussion and analysis, and consolidated financial statements. These documents have been filed with the Canadian Securities and Regulatory Authorities of the U.S.

Securities Commission and are available on the company's corporate website. Before we begin, I'd like to remind you that all amounts discussed today are in Canadian dollars, and today's remarks contain forward-looking information that represents our expectations as of today and accordingly are subject to change. We do not undertake any obligation to update any forward-looking statement, except as may be required by Canadian and U.S. securities laws.

A number of assumptions were made by us in preparing these forward-looking statements, which are subject to risks. Results may differ materially from what is projected, and details of these risks and assumptions can be found in our filings on SEDAR and with the Securities and Exchange Commission. Joining me on the call today, we have Michael Cammarata, our president and chief executive officer; Dr. Toni Rinow, chief financial officer and global chief operating officer; and Kelly Kosmin, general counsel.

Toni will begin the call by providing an operating update and a review of our third-quarter financials. Kelly will follow with a review of our recent acquisition of Sprout, and Michael will follow with an update on our strategic path. Now, I will turn the call over to Toni. Toni, please go ahead.

Kelly Kosmin -- General Counsel

Thank you, Toni. I'm thrilled to be joining the Neptune Wellness team as its general counsel. I'd like to take this opportunity to discuss our recent acquisition of Sprout brands and Morgan Stanley's relationship in more detail. Last week, we announced our acquisition of Sprout Foods, a three-brand portfolio of organic, plant-based baby food and toddler snacks.

Sprout is a great fit for Neptune as the products, people, and corporate philosophy fit perfectly within the transformation we are undergoing. Sprout's three brands: Sprout, Nosh, and NurturMe are disrupting the baby food market, which has historically been dominated by processed foods. With roughly $28 million in annual net revenues, Sprout already has a foothold in the organic baby food market. We see significant revenue and cost synergies with this acquisition.

On the revenue side, we believe that our distribution network, both in the U.S. and internationally, can provide early additional distribution points for existing Sprout products. We also see opportunities for product expansion within Neptune's portfolio, for example, in our nutraceuticals business. On the cost side, we expect to be able to provide benefits from our manufacturing capabilities, as well as through our combined retail relationships.

We are very excited to have Sprouts in our portfolio, and we look forward to sharing more of our plans for the company as we move forward. Our acquisition of Sprout also begins a new important relationship for Neptune with Morgan Stanley. Prior to Neptune's acquisition of the majority of Sprout's outstanding shares, Morgan Stanley was Sprout's largest shareholder. With this transaction, Morgan Stanley is now a significant shareholder of Neptune, and Lincoln Isetta from Morgan Stanley has joined the Sprout Board of Directors.

Sprout could not be better positioned for success as part of Neptune's growing brand portfolio. Additionally, Neptune has a full pipeline of future M&A opportunities before us, and we will continue to expand our brand presence in North America and internationally. I will now turn the call over to our chief executive officer and president, Michael Cammarata, to discuss the company's strategic initiatives.

Michael Cammarata -- President and Chief Executive Officer

Thank you, Toni, and Kelly, and good morning, everyone. I echo Kelly's sentiment on the Sprout's organic foods transaction and the relationship with Morgan Stanley. We expect the acquisition to have more value than it appears at first glance. We see Morgan Stanley as more than a new shareholder, but as a partner in our long-term growth strategy as we will be working together to identify future mergers and acquisitions opportunities.

We see Sprout as a key part of our portfolio of innovative and disruptive brands in the plant-based health and wellness area. Neptune is becoming a brand accelerator, and we believe we can continue to grow Sprout's brands with additional points of distribution and a larger product portfolio. We are excited to realize that the synergies that will come from having Sprout's and its three brands as part of Neptune. The acquisition of Sprout comes after historical third quarter for Neptune as we move from B2B extraction to finished form, branded product revenues at our Sherbrooke Facility.

We are now have the capability to produce multiple product lines at this facility. We are licensed from products from team shows to distillate, to CBD, and gummies. Although our revenues were impacted by the transition from extraction in the third quarter, this shift will lead to a higher and more sustainable margins, and the ability to create brand loyalty for our high-quality cannabis products. As Toni mentioned, we are extremely pleased with the early success of Mood Ring in British Columbia.

The initial numbers beat both our expectations and those of the territory. We are now in 150 points of distribution, which we estimate to be around 20% to 30% of the BC market. The Mood Ring products have sold out online and through distribution channels, as we have ramped up product to meet the higher-than-expected demand in BC, and we will be rolling out additional territories in Canada in the upcoming quarters, including Québec. It is important to note, as Toni mentioned, that the current Canadian accounting rules do not allow us to book revenues for these products until we receive the sell-through data from the individual retailers, and the timing may vary by retailer.

We expect to start booking modest revenue from these products in Q4. We believe that our relationships and our experience in this market through our previous extraction business has allowed us to make this shift into B2C products efficiently and will further allow us to ramp up the businesses over the next year. We have also made some exciting changes recently in our nutraceutical business. We have brought on a new general manager to run this business and are making changes to increase efficiency and accelerate innovation.

For example, we have made the decision to consolidate the nutraceutical offices into our headquarters in Montreal, which we will expect to lead to lower costs and increase collaboration. This focus on efficiency is already bearing fruit as their team has presented multiple products and revenue opportunities to senior management. We will update you with more details as these opportunities are realized. In the health and wellness space, we are anticipating several product launches in the near future.

As we discussed, the fulfillment of our earlier purchase orders was delayed in Q3, and we are starting to see improvements in Q4, and we expect a more meaningful fulfillment uptick by Q1 as logistical barrier is clear and product availability improves. We have been pleased so far with our Amazon relationship, and we expect the volumes through Amazon to increase in the upcoming quarters. We are focused on achieving an improved gross profit margin as we move our health and wellness brands forward. We are also excited to talk about the launch of our Forest Remedies brands.

We have had discussions with 39 retailers thus far, and we expect to have product available both online and in-store within six months to a year. We will start to report on more details after completing these discussions with the retailers. At a corporate level, there are several recent initiatives I would like to highlight. Our new SAP implementation is expected to go live on April 1st, and we expect this initiative to help us contain our cost and support our growth trajectory.

We are excited to introduce today our new general counsel, Kelly Kosmin. Kelly comes to us from a cost of sales and marketing and will be leading our legal HR and strategic initiatives. We expect Kelly to be an integral part of our growth strategy as we negotiate and solidify an increasing number of retailer and supplier relationships. We are exploring ways to monetize our P&L as we move to a CPG model, especially, in how we report costs.

These changes will likely come next fiscal year, and we hope they will provide invested with more insight and transparency into our business structure and the opportunities that will come with increased scale. We are also updating our corporate and individual brand websites to better align with our new products and our strategy. We think you will be impressed by what you see. We have also been laying the groundwork for our environmental, social, and corporate governance strategy, which is commonly referred to as ESG.

ESG will be a key pillar of our corporate philosophy. For Neptune, ESG will not be an asset [Inaudible]. It will be core to our strategy and operations. Some recent ESG achievements include a higher proportion of women's staff members.

Over a year ago, our workforce was less than 23%. Now Neptune is at 41%, well on our way to our goal of 50-50. We note that this is inclusive of our factories. We are making progress of our goal of introducing carbon-negative products with an overall company goal to be carbon negative.

This means our products and our business operations will have a positive environmental impact. We are proud of the steps we are already taking. For example, packaging for our adopted Jane Goodall products has environmental-friendly benefits, including nutrition for bees when it is planted in your backyard. We will be talking more about these plant-based product innovations in the upcoming quarters, including some new exciting omega-3 products.

We have a world-class team of product innovators and developers at Neptune committed to leading this plant-based revolution. Finally, I want to say a few words in the cannabis in the United States. With the new administration and the shift in control of the Senate, we believe that the changes to the legal status of cannabis are now more likely than they've ever been before. We have adapted our strategy to be preferred, if and when legal changes related to cannabis occur.

However, our long-term strategy does not depend on legalization, and we have significant growth opportunities ahead of us, regardless of any changes in the legislation process. 2020 was an exciting year for Neptune as we navigated a transformation to a CPG platform in the midst of COVID-related volatility. As you can see from our recent Sprout acquisition, we are accelerating our momentum of change, and we look forward to reporting on more exciting initiatives ahead. We have made profound changes to our business, and we could not have achieved this transformation without the dedication of our employees.

I want to take this moment to thank them for their efforts, and I'm excited about many of the opportunities that lay ahead of us. Neptune is dedicated to making products that have a positive impact on individuals and the planet. We believe there is a tremendous market opportunity for plant-based products, and we look forward to updating you each quarter on our successes. And now I will turn over the call to the operator for questions.

Questions & Answers:


Operator

[Operator instructions] Your first question comes from the line of Aaron Grey with Alliance Global Partners. You may now ask your question.

Aaron Grey -- Alliance Global Partners -- Analyst

Hi. Good morning, and thank you for the questions. So my first question is kind of regarding the hand sanitizers, some of the supply chain issues that you kind of mentioned during the quarter, and specifically how it relates to the status of the $100 million of purchase orders that you had previously mentioned on the last call. So you had mentioned December kind of a delay to 4Q fiscal 2021 or beyond.

It sounds like you're starting to see some improvement into 4Q, and you mentioned to see more next quarter. But I just wanted to know if we can get some more clarity. You had first put out the price we have in December now. A couple of months removed from that.

So I just want to get more color in terms of whether it was more related to kind of air versus now C shipping? And with that kind of being two months removed, kind of further color on changing the transition you've kind of seen up to date. To those kind of supplies being able to come in now and kind of get those sold. You mentioned shifting some supply as well within MD&A from Mexico, too. So just any kind of incremental color you can give in terms of some of these supply chain issues and how it relates to those purchase orders, which you said are still in place, but also they mentioned there being some kind of issues with inventory and the repurchasing orders for those products as well.

So kind of any incremental color you could give there would be helpful. Thanks.

Michael Cammarata -- President and Chief Executive Officer

Yeah, I'll take that. It's Michael Cammarata. So the purchase orders are not related to hand sanitizers, the $100-plus million purchase order. So that's coming up with a different product line.

Regarding hand sanitizer specifically, we did have to shift out some of our international inventory to domestically made -- U.S. made all products for some of our retailers. And we did see that there is a switch in demand on the consumer side. So they're normalizing their levels at retailer.

So the unique thing that we were able to do was actually be able to develop a U.S. made high-quality product that actually doesn't leave that sticky feeling or anything along those lines. So our product is superior and been getting great reviews. And we've had a lot of success with sustaining retail distribution in the hand sanitizer market and having opportunities to pick up additional distribution points.

So our hand sanitizers have evolved to our latest formulation. We are also introducing Dr. Jane Goodall's natural plant-based hand sanitizers. That will be rolling out to retail.

So we feel that we have a competitive edge, both on the product formulation with Dr. Jane Goodall's plant-based natural product that's entering the market for hand sanitizers. And then our Neptune brand hand sanitizers, which we've moved to a U.S. made and manufactured.

And we've also lowered the cost of the manufacturing to be very highly competitive in the hand sanitizer market and to be able to retain margin. When it shifts to the $100-plus million purchase orders that we discussed, the international supply chain issues that we've seen was twofold. One, when air freighting product, the cost would normally be around $200,000 to $300,000 and accelerated to over $1.3 million. We are competing with product launches with Apple and others and Microsoft internationally at the end of our year -- our calendar year.

And then it shifted to us moving to containers and shipping it across the seas, those products for those purchase orders, then we saw a shortage -- global shortage of containers. So we've had twofold hit us with fulfilling those, but we're committed to focusing on the profitability and not just rushing in orders to make timelines. We want to build a sustainable long-term business, and we want to grow our profit margins. And also, we've been looking at our P&L to even give more transparency, and we've been working with our accounting teams and even the former CFO of Unilever to be able to monetize our P&L to be able to -- of North America, but monetize our P&L to be able to better reflect true direct cost to what it costs us to make the products.

So the investors can see more along the lines of what the gross profit margin is in each sale. So regarding the hand sanitizers, we've switched out of any supply that was international to domestically made in the U.S. We are working with our retailers, not only on our Neptune brand but our Dr. Jane Goodall hand sanitizers that's launching.

Both have higher qualities and competing heavily with brands that have been in that industry for a long time. And then internationally, regarding the backfill purchase orders that we have, we are putting things on cargo ships. We had a little bit of issues with getting containers. We're starting to see improvements in the global supply chain.

A lot of the components for those products come from overseas. And we expect to start seeing improvements -- modest ones in Q4 and then expanding, obviously in Q1. I think I got all the questions on there. I think I can [Inaudible] on there.

Aaron Grey -- Alliance Global Partners -- Analyst

OK. Thanks. No. Thanks, Michael.

I appreciate the commentary there and details. I appreciate the commentary there and details. So second question for me. Congrats on the Sprout acquisition.

So kind of mentioned a little bit of detail there on the potential kind of synergies you guys see, particularly on the top line. Related to that, in terms of the points of distribution, could you provide kind of some timing in terms of how you expect to be able to realize some of these synergies? And more color specifically in terms of the points of distribution you expect to be realized through the acquisition and how you guys look to leverage your own kind of distribution platform related to that?

Michael Cammarata -- President and Chief Executive Officer

Yeah. Yes. So I think we're already starting to see, and we've been working on a plan that maximizes the synergies before the -- between both entities. The couple of parts of the synergies.

One is on a cost basis. We're looking to -- as a portfolio of three brands to synergize all three of their supply chains to improve gross profit margin to give us an extremely good positioning on that. With the distribution, we've had success internationally expanding distribution for them that will start taking place in upcoming quarters with onboarding additional international customers. And then domestically, they will be rolling out chainwide to target over 1,200 stores, eight SKUs in upcoming months.

So we've seen domestic success in distribution. We're adding international distribution. We have a great team in our health and wellness division as we've had to build our global supply chain through the COVID times. That comes over from Walmart.

So we've been definitely thoroughly looking at how the opportunities are. They do have a great reputation and been strong in the domestic distribution. So adding Target was definitely something that we're really excited about. And then internationally, expanding the footprint overseas, the products will be shown at the Dubai Food Show coming up as well.

And we are working actively on completing the registrations in over 20 countries. So that's something that you'll see in international growth from. You'll see domestic growth in the U.S. distribution.

And also, within Canadian, we're onboarding a Canadian retailer grocery store as well. So you're going to see growth simultaneously, domestically and internationally, and also cost synergies for the three brand portfolios. And we're really good that Morgan Stanley and the management stayed on to support the growth and been working with us on the plan, and we're really excited to bring it to fruition and really starts our footprint in the plant-based foods area, and we expect a lot of product innovations. It will also be very supportive to our nutraceutical business.

As I talked about a little bit, we're looking for synergies on vitamins and expansions. And is a heavy interest in kids vitamins and other products. So you expect to see line synergies between our nutraceutical side on the product development area as well.

Aaron Grey -- Alliance Global Partners -- Analyst

OK. Thanks for the color. Thank you. And if I could just squeeze in one more.

You mentioned that you expect further M&A. So just any kind of color on potential targets and synergies that you would expect there, too, would be similar along the lines of just saw with Sprouts kind of in those help to modify products that are kind of smaller and growing can benefit from your distribution platform? Or any kind of color in terms of different verticals or a supply chain you'd expect for the M&A to occur would be helpful? Thanks.

Michael Cammarata -- President and Chief Executive Officer

Yeah. We're looking heavily in plant-based arena, Personal Care, Home Care, Households and then obviously, plant-based foods. And so -- and also tactical infrastructure support because as we've started -- as our brand is starting to go to distribution and scaling, we want to be able to continue to be able to support our brands from e-commerce to all the way into international and domestic North America focused growth. So when I looked at brands, it's really looking for brands that of purpose that fit within our values.

We are obviously trying to set our ESG strategy very in line with our consumers. And I think that the brands that we're looking at and opportunities that we see are really some brands that are historical and some brands that have the momentum and that align with our philosophies. So we're definitely looking the cross-category because we have a platform that we've built out over the last 1.5 years that can support a lot of brands and distribution globally and domestically. And we've made a lot of optimizations in our supply chain, both having domestic supply chain and focus in North America, but also in international supply chain.

So we want brands that will be synergistic that will add to our gross profit margin and our top line and bottom lines.

Aaron Grey -- Alliance Global Partners -- Analyst

Great. Thanks for the color. And I'll pass it along.

Operator

Your next question comes from the line of Gerald Pascarelli with Cowen. You may now ask your question.

Gerald Pascarelli -- Cowen and Company -- Analyst

Hi. Good morning. Thanks very much for taking the questions. So just going back to the purchase orders, specifically related to 3Q on the shift or on the delay in revenue recognition.

Can you quantify what you believe the impact was to your 3Q revenue, specifically as it relates to the purchase orders? Thank you.

Michael Cammarata -- President and Chief Executive Officer

Toni?

Toni Rinow -- Chief Financial Officer and Global Chief Operating Officer

Sure. Can you hear me well, hopefully? So we -- these purchase orders that we had announced throughout Q3, and that Michael just mentioned, are not related to hand sanitizers. They are all intact. So we are currently negotiating with suppliers to deliver these products to our different clients.

It is difficult to say how much they are on a quarter-by-quarter basis because these are long-term purchase orders. We believe that we are going to fulfill them as soon as those international trade challenges are being resolved. Our goal is to transport profitable merchandise and to make these business lines -- gross margin profitable. And in Q3, that was just not possible for those international challenges.

So we believe that those purchase orders, they will unfold over the next quarters as those supply chain challenges are easing up, and they stay to be all intact, and they are related to different Neptune Innovation products.

Michael Cammarata -- President and Chief Executive Officer

And I'd also want to add, too, we've been very fortunate that one of our CPG partners, Unilever has entered into that category, and we'll be supporting manufacturing in that effort. So we do see that some of our synergies with our CPG partners have helped us broaden our supply base for those particular products that we are launching.

Gerald Pascarelli -- Cowen and Company -- Analyst

Got it. Thanks very much. So it's mid-February, we're -- I guess, halfway through fiscal -- through your fiscal 4Q. Not looking for guidance or anything like that, but if there's any kind of color you can offer just in terms of how your revenues are trending quarter-to-date maybe relative to the previous quarter, maybe year over year? Any broad color you can provide there would be helpful.

Thank you.

Toni Rinow -- Chief Financial Officer and Global Chief Operating Officer

Sure. So yes, and for the reasons that we have seen in the past that we are not providing a guidance because even though the year-over-year growth is there, but from a quarter-to-quarter perspective, revenue growth can be much more scattered. So -- but just in order to give you an idea of overall trend, we -- I believe that in this quarter, Q3, we have gone through the dip, and we're now moving back up. So, yes, I think that's a fair first statement to say that we have moved through the more difficult time for us and moving back up.

And I think what we can also see is that we will -- we will increase in Q4. And year over year, I think you have seen that we are kind of close to doubling revenues fiscal year over year after nine months. And I think that trend certainly continues.

Michael Cammarata -- President and Chief Executive Officer

And I'll add, too, that we also -- one other thing on the Sprout's brand, we've actually had very good talks with Tesco. So you'll -- on the international footprint. So that would be another distribution point to the earlier question.

Gerald Pascarelli -- Cowen and Company -- Analyst

Got it. Thanks, Michael. Thanks, Toni. Just last one for me.

This is on SG&A. Obviously, it was inflated this quarter due to the one-off big depreciation and amortization, but excluding that, from an absolute dollar perspective, it did go down sequentially. So I guess as we look at the SG&A line, I know that there was a 25% headcount reduction. Is that fully baked into that adjusted number, which, according to my math, it's about $17.5 million for the quarter? Or is there more white powder in terms of how you can leverage your SG&A line going forward as we look out to fiscal '22? Thanks.

Toni Rinow -- Chief Financial Officer and Global Chief Operating Officer

Yeah. So in Q3, as you say, most of the SG&A and the measures we have taken are fully baked in. So yes, we have a couple of noncash that we have identified in the EBITDA adjustment in SG&A and some accelerated depreciation. So mostly the SG&A, yes, it went down because we -- as you all know, we are managing our cost -- internal cost structure extremely carefully.

And that will continue to go on because our goal is still to work ourselves over the next fiscal years to EBITDA positive. So most of that indeed was baked in for Q3.

Michael Cammarata -- President and Chief Executive Officer

And I'll even add to that. It's definitely -- we're looking to -- on a year-over-year basis to obviously grow top line and also improve cost. And I think we're on the trajectory to do that.

Gerald Pascarelli -- Cowen and Company -- Analyst

Thanks very much. I will hop back into the queue.

Operator

Your next question comes from the line of John Chu with Desjardins Capital Markets. You can now ask your question.

John Chu -- Desjardins Capital Markets -- Analyst

Hi, good morning. My first question is just on the hand sanitizer outlook. You talked about oversaturation impacting demand. But I was also under the impression you're expanding into Costco's West Coast and U.S.

Midwest retail outlet there. So can you maybe just talk about whether or not you did expand into that or whether or not that did not happen, and that also contributed to the decline in the hand sanitizer revenue?

Michael Cammarata -- President and Chief Executive Officer

Yeah. I think there's two parts to that. We have a great relationship with Costco, and we'll be launching products with them and working with them on new product lines. When it comes to the particular hand sanitizers, they had -- some retailers, not just Costco, but other retailers had to move out of different brands, and it takes some time to sell-off.

So for instance, some retailers had 18 other brands. And then the retailers have cut it down to three or less, and we've been made the cuts, but we're not going to be able to see the growth until they move through 18 other brands worth of hand sanitizers. The good thing that we have noticed on the different distribution points that we're in is that our brand is performing much better than the peers and competing with some of the biggest brands in hand sanitizer. We have seen some of the big competitors in hand sanitizers actually lose money to try and win back real estate from us.

And we're committed to profitability and focusing and developing long-term relationships with not only the consumers but our retail distribution partners. And so we do feel that we're in a good position, and we're starting to see good movement, obviously, because of our sales data on our particular brand, but also real estate to start to open up. I think Q4 would be more like a stabilization side but across the board. But I think as we move into Q1 and Q2, we should start to see the uptick and hand sanitizes as a business unit.

And I think that's something that Neptune has done very good over the last year is to have multiple product lines. And to be able to adapt with demand on the consumers, but also be able to hold our product lines to the highest standard and also work with global and domestic supply chain that's seeing improved gross profit margins to be highly competitive against some of the biggest brands in the world.

John Chu -- Desjardins Capital Markets -- Analyst

OK. So as a follow-up, you recently got some approval on the disinfectant wipe side. What's the timing for that? And is there any risk that by the time you're trying to get your market out to the retail market that you could see an uptick in a more oversaturated market similar to what we saw in the hand sanitizer side?

Michael Cammarata -- President and Chief Executive Officer

So when it comes to disinfectant surface wipes, they're regulated by the EPA in the states in different bodies across different countries, the barrier to entry is much harder, similar to our Cannabis business, right? The licenses that we've had to attain and get, take years and months and require a lot of work to you. The EPA is very similar when it comes to licenses in the U.S. and the different bodies in Canada and other countries. The format that we have on wipes, is going to be a lot of B2B businesses as well.

So, they're more contract oriented. So, commitments that are longer term. And we're even seeing that across some of our other portfolio products in our health and wellness space. That we're negotiating on contracts that could last for three years, four years and that are very unique to us.

So it's not as easy for other like brands that came in during a pandemic time but didn't focus on quality. They're still sitting on shelves or are products that are focused on quality sold out and the retailers are moving out of those products. When it comes to wipes, those are heavily geared to a lot of B2B customers, so government and businesses and such and different territories with a high standard of licensing and requirements. So I think that the wipes are uniquely positioned for a longer-term, stable business and growth because of contract base, not necessarily all just retail focused, and there's not a lot of competitive brands in that space.

John Chu -- Desjardins Capital Markets -- Analyst

OK. That's helpful. And then maybe just a last question on the Mood Ring launch. I don't see any products listed in OCS yet and maybe give us a sense on when you think you might be entering Québec with that product brand as well?

Michael Cammarata -- President and Chief Executive Officer

I think we have a press release coming out pretty shortly. And Toni can talk about that.

Toni Rinow -- Chief Financial Officer and Global Chief Operating Officer

Yes, yes. Good question. So we are in very close conversations with SGDC. They like very much what we do.

We have a new brand that we're going to announce very, very shortly. So you should stay tuned. And essentially, what they told us is that whatever you produce, we take. So they're looking for good products for high-quality products.

Our launch in the rest of Canada was extremely successful. The products are very high-quality for hashish. We had coverage like this is the best hashish out there. So we are looking very -- we're looking forward very much to Québec, and it should be coming very, very shortly.

So just stay tuned on that one.

Michael Cammarata -- President and Chief Executive Officer

And I'll add that, that was a unique and larger unique situation because it's how we're -- like in the U.S., we're working with the retailers to develop brands, partner with them and to bring brands and collaborate with them when we launch new brands. To get faster distribution and more points and more support. But in Canada, we actually -- in this scenario, we created a brand with a territory to launch, and we're really excited about it. So yes, it's not going to be listed on the Mood Ring.

It will be listed on the brand network, that we're going to be launch -- announcing with that territory shortly.

John Chu -- Desjardins Capital Markets -- Analyst

OK. Thanks. I'll get back in the queue.

Operator

Your next question comes from the line of Doug Miehm with RBC Capital Markets. You now ask your question.

Doug Miehm -- RBC Capital Markets -- Analyst

Yes. Good morning. A couple of questions. Starting with the U.S.

opportunity. I know, Michael, that you walked through what Senator Schumer and Booker talked about recently, and I hope to see that news soon. But maybe you can give us a little bit more information on your thinking with respect to the U.S. opportunity, and especially in light of the fact that you did writedown the SugarLeaf assets again.

Just compare and contrast what you've done there?

Michael Cammarata -- President and Chief Executive Officer

Yes. So actually, the writedown is in correlation with us making transition in the U.S. So the goodwill and impairment, on that accountant, but Toni can maybe add more color after I speak. But is -- when it was written, was tied to specifically hemp extraction, right? So as we're making the shift, like we did in Canada, to go from just extraction to finished form.

It obviously had an effect on the goodwill and the impairments. So as we're looking at SugarLeaf Labs facility, and focusing more on our finished form products to be ready for any shift and beyond extraction because we give much more value when we can control the whole quality process from extraction to the finished form. And we're seeing that with the reviews that we're getting in Canada and the quality scores, like our distillates, like our teams that we've been working on -- in Canada on. Our distillates yielding more than -- almost 98% to almost 99%.

So we're in a very good situation with quality and experience. So as we're looking at that facility in the U.S. that we have, particularly the one that relates to the impairment, we were looking at broadening the uses of that facility to finished form and to -- from extraction all the way to packaging. And because we made -- we're making these changes with the business model in that area to move away from extraction to finish one product or branded revenues as we're launching brands, both in Canada and the U.S.

that was something that triggered because of how it was written prior and the acquisition, and a goodwill was tied to pacifically hemp for extraction for particular customers. So as we changed the model, we're focusing on Fortune 100 customers, and we're focused on Fortune 500 customers, and we're focused on making finished form, not just doing extraction for farmers. So that is -- that had to play into it. And if Toni wants to add any more to that, she can.

Toni Rinow -- Chief Financial Officer and Global Chief Operating Officer

Yes. I think, Michael, you sort of -- you said it perfectly well. I don't think there was much to add at this point unless there is a more specific question.

Doug Miehm -- RBC Capital Markets -- Analyst

OK. No that's fine. I think you did a great job answering that.

Toni Rinow -- Chief Financial Officer and Global Chief Operating Officer

Yes.

Doug Miehm -- RBC Capital Markets -- Analyst

The second question, and maybe this has just been a mischaracterization, and this is probably a question for Kelly. With respect to Sprout Foods and the MD&A, it appears that the company has been included in a U.S. House subcommittee investigation on heavy metals. And one of the things that we saw in the Reuters article last night was that, I guess, yourselves and two other companies refused to cooperate with the investigation.

Is this a mischaracterization on inflammatory or something else or is it an accurate representation of what's going on there?

Kelly Kosmin -- General Counsel

Yeah. Thank you for the question. This is Kelly. So I'll start by saying that it's an inaccurate representation prior to Neptune's acquisition of Sprout.

Sprout had gone through at least two changes in leadership and all of these activities that you're reading about currently in the news actually occurred -- started back in 2019, early 2020. And at that time, it was a voluntary -- it was a lobbyist group and advocacy group for baby food. And some companies chose to participate and basically submit in information concerning their product lines. And those companies that chose to participate ended up getting smeared in the press for their participation.

The leadership at Sprout back at the time, none of whom are still currently with the company thought the more prudent approach would be to just lay low and not get caught up in this press campaign. So as part -- so saying that they refuse to comply is an interpretation of they chose not to participate because it would appear that no good deed would go unturned in this situation. So as part of our due diligence of our Sprout acquisitions, we are aware of this issue. We recognize that it's an issue that actually occurs in the entire food chain.

It's not simply limited to baby food products. And we are going to take the position and have been in discussions with Sprout and outside parties that we are going to be a partner in the industry. We will cooperate with the commission inquiry, and we want to be involved in a positive solution to this issue throughout the industry. So we will be actively participating and partnering with others in the industry to find solutions.

Michael Cammarata -- President and Chief Executive Officer

Yeah. And I like to even add, like this is what Neptune health and wellness is about. We're going into the plant-based area because we want to raise the standards. The fact that in baby food, particularly was one area, but the whole U.S.

supply chain, everything from your pickles to other products has heavy metals into it. And what we're trying to do is not just to meet or exceed the FDA requirements, but actually bring a new standard at a much higher level. So whether it be cannabis in Canada with us introducing MaxSimil, which is our IP that is very unique, and people typically tie it to omega-3s and krill oil. But MaxSimil, actually is an enzyme that bypasses a digestive system and maintains that ingredient at a much higher level, so it goes directly into your system.

So in a cannabis use, if you put MaxSimil with CBD or THC, it's an onset within two minutes versus people having an edible and laying 30 minutes, not feeling anything and having too many edibles and ending up causing havoc on a health system. So, we have IP that's very unique to us that can make products safer, like we're doing in Canada that we'll be introducing MaxSimil with some of our products. We have a clinical study going on right now. And so, the opportunity here for Neptune to really disrupt the CPG industry has never been greater.

And I think that when you look at Sprout's, and it's been around for a long time, and it has very loyal customers and distribution platform and meet or exceeds. And the fact that Morgan Stanley is our partner and work with us on the strategic planning of Sprout and its distribution, and its changes, and even in our growth opportunities, and synergies of other products that we'll launching, I think we're very uniquely positioned to not only meet or exceed requirements in the territories we operate, we're going to be very active in raising the bar, not only for plant-based foods and the -- specifically in the U.S., raising the bar across the whole U.S. supply chain because I think that that's something that we have an opportunity to raise the bar and the standards and really connect with our consumers, and that's the type of brands that we're looking at, that have the same philosophy as us.

Doug Miehm -- RBC Capital Markets -- Analyst

OK, very good to know. Thanks, Michael, Kelly.

Operator

[Operator signoff]

Duration: 56 minutes

Call participants:

Unknown speaker

Kelly Kosmin -- General Counsel

Michael Cammarata -- President and Chief Executive Officer

Aaron Grey -- Alliance Global Partners -- Analyst

Gerald Pascarelli -- Cowen and Company -- Analyst

Toni Rinow -- Chief Financial Officer and Global Chief Operating Officer

John Chu -- Desjardins Capital Markets -- Analyst

Doug Miehm -- RBC Capital Markets -- Analyst

More NEPT analysis

All earnings call transcripts

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Neptune Wellness Solutions Inc. Stock Quote
Neptune Wellness Solutions Inc.
NEPT
$0.14 (-1.31%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.